Rio Tinto PLC (LON:RIO) “Sell” Rating Reconfirmed by Analysts at Liberum Capital; With GBX 2750.00 Target; Catabasis Pharmaceuticals, Inc. (CATB) Had 4 Bulls

Rio Tinto plc (LON:RIO) Logo

The company have set price target of GBX 2750.00 on Rio Tinto PLC (LON:RIO) shares. This is -23.54% from the last stock close. In analysts report released on 9 April, Liberum Capital kept their “Sell” rating on shares of RIO.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals has $27 highest and $1.5 lowest target. $4.76’s average target is 168.93% above currents $1.77 stock price. Catabasis Pharmaceuticals had 15 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Monday, August 14 with “Buy”. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Buy” rating given on Monday, August 14 by Wedbush. The rating was maintained by Wedbush with “Outperform” on Tuesday, March 20. The firm has “Hold” rating given on Thursday, August 10 by Cowen & Co. The firm has “Buy” rating by Citigroup given on Thursday, June 9. Citigroup maintained the shares of CATB in report on Tuesday, March 22 with “Buy” rating. The firm has “Buy” rating given on Monday, August 17 by Wedbush. The rating was maintained by Cowen & Co with “Hold” on Thursday, October 5. On Monday, August 14 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Outperform” rating by Wedbush on Wednesday, June 8. See Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) latest ratings:

20/03/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $5 New Target: $6 Maintain
20/11/2017 Broker: Citigroup Rating: Buy New Target: $2.5 Upgrade

The stock increased 0.69% or GBX 24.5 during the last trading session, reaching GBX 3584.5. About 712,963 shares traded. Rio Tinto plc (LON:RIO) has 0.00% since April 9, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 29 analysts covering Rio Tinto PLC (LON:RIO), 17 have Buy rating, 2 Sell and 10 Hold. Therefore 59% are positive. Rio Tinto PLC has GBX 4700 highest and GBX 3 lowest target. GBX 3458.42’s average target is -3.52% below currents GBX 3584.5 stock price. Rio Tinto PLC had 538 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Macquarie Research with “Outperform” on Friday, February 2. The stock of Rio Tinto plc (LON:RIO) has “Buy” rating given on Tuesday, October 11 by UBS. As per Wednesday, August 3, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by Deutsche Bank on Tuesday, February 7. The firm has “Buy” rating by Deutsche Bank given on Thursday, July 28. On Wednesday, December 9 the stock rating was maintained by Canaccord Genuity with “Buy”. Deutsche Bank maintained Rio Tinto plc (LON:RIO) on Wednesday, October 14 with “Buy” rating. The firm earned “Sell” rating on Tuesday, November 3 by Liberum Capital. The stock has “Buy” rating by Deutsche Bank on Tuesday, December 5. Credit Suisse maintained the shares of RIO in report on Monday, November 30 with “Neutral” rating.

Rio Tinto plc, a mining and metals company, finds, mines, processes, and markets mineral resources. The company has market cap of 62.38 billion GBP. The firm mines and produces aluminum products, including bauxite, alumina, and aluminum; copper, gold, silver, and molybdenum, as well as nickel; diamonds, titanium dioxide feedstocks, borates, and salt, as well as high purity iron, steel billets, metal powders, zircon, and rutile; uranium; iron ore; and thermal coal, and coking or metallurgical coal. It has a 7.36 P/E ratio. The Company’s products also comprise others, such as sulphuric acid, rhenium, lead carbonate, and selenium.

The stock increased 0.57% or $0.01 during the last trading session, reaching $1.77. About 101,316 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has risen 19.23% since April 9, 2017 and is uptrending. It has outperformed by 7.68% the S&P500.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Chart